Activity of cabozantinib after immunotherapy in advance kidney cancer

A retrospective study published in the European Journal of Cancer this month looked at the activity of cabozantinib after immune checkpoint inhibitors in people with metastatic clear cell renal cell carcinoma (RCC). The overall response rate was 36%, with a median overall survival of 13 months. Cabozantinib appeared to be well tolerated and there were […]

read more

Positive results from trial of cabozantinib plus nivolumab combination in untreated metastatic kidney cancer

Results from the pivotal phase 3 CheckMate-9ER clinical trial evaluating nivolumab (Opdivo) in combination with cabozantinib (Cabometyx) compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma (RCC) were released today. These top-line results were positive for the combination treatment, which improved progression-free survival, overall survival and objective response rate compared to sunitinib. […]

read more

Cabozantinib in combination with immunotherapy for advanced kidney cancer

In this video interview, Dr Monty Pal from the City of Hope cancer centre in California, USA, talks about the clinical trials involving cabozantinib in combination with atezolizumab for clear cell and non-clear cell renal cell carcinoma (RCC). Watch the video interview on Practice Update here  

read more

Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer

A recent literature review and network meta-analysis of phase 2/3 randomised, controlled clinical trials of approved first-line tyrosine kinase inhibitors (TKIs) involving more than 4,200 patients with metastatic renal cell carcinoma (RCC) has shown that cabozantinib, sunitinib, pazopanib, and tivozanib have similar efficacy, but tivozanib’s safety profile is superior to the profiles of the other […]

read more

IKCS 2019: Biomarkers in kidney cancer

In this interview taken from the International Kidney Cancer Symposium (IKCS) 2019 held in Miami, USA earlier this month, Dr Tian Zhang, from Duke University talks about existing and emerging immunotherapy biomarkers for kidney cancer, and the PEDIGREE study. Dr Zhang talks about PBRM1, PD-L1, and tumour mutational burden as prognostic biomarkers, and angiogenesis, CD8-infiltrating […]

read more

Deciding on the ideal first-line treatment for rare and advanced kidney cancer

Currently, doctors are unsure which is the best first-line treatment for patients with rare and advanced kidney cancers. During a debate at the 18th International Kidney Cancer Symposium (IKCS), 5 doctors discussed their opinions. During the debate, the use of immunotherapy versus targeted kinase inhibitors (TKI) for the first-line treatment of advanced non-clear cell renal […]

read more

PD-L1 expression and clinical outcomes with targeted therapy

A recent study published in Clinical Cancer Research analysed tumour tissue samples obtained in a clinical trial to investigate how the expression of the PD-L1 receptor on the tumour cells influenced outcomes in patients with metastatic renal cell carcinoma (RCC) receiving targeted therapy. Positive expression of the PD-L1 receptor on RCC tumour cells was associated […]

read more

Phase Ib cabozantinib plus atezolizumab combination study now open to kidney cancer patients in the UK

Based on promising efficacy findings, the COSMIC-021 clinical trial has been expanded from the original two indications (non-small cell lung cancer (NSCLC) and prostate cancer) and is now open to patients with renal cell carcinoma (RCC), urothelial cancer, breast cancer and ovarian cancer. The phase 1b, open-label trial assesses the combination of cabozantinib (Cabometyx) and […]

read more

Telaglenastat/cabozantinib combination shows early activity in metastatic kidney cancer

Telaglenastat is an oral glutaminase inhibitor and this is the first time it has been administered to humans. Glutaminase is a key enzyme that controls the glutamine pathway that is prominent in renal cell carcinoma (RCC) and important for the tumour to thrive in the body. In pre-clinical models, telaglenastat was found to synergise with […]

read more

Real-world outcomes of nivolumab and cabozantinib for metastatic kidney cancer

A retrospective study using data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) dataset looked at the efficacy of nivolumab (225 patients) and cabozantinib (53 patients) when used to treat metastatic renal cell carcinoma (RCC) in the real world. The study found similar outcomes for patients treated with nivolumab and cabozantinib in the […]

read more
Showing 1 to 10 of 64 results
  TOP